Abstracts Archive - Page 932 of 2425 - ACR Meeting Abstracts

Abstract Number: 2605 • 2019 ACR/ARP Annual Meeting
Men and Black Persons Die at Younger Ages from Systemic Sclerosis: A Nationwide Population-based Study
Ram Raj Singh¹, Devanshu Singh ² and Eric Yen ¹, ¹UCLA, Los Angeles, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Systemic sclerosis (SSc) is more common in women than men, but men tend to have a faster disease progression than women. However, conflicting results…
Abstract Number: 2606 • 2019 ACR/ARP Annual Meeting
Evolution of Systemic Sclerosis-Related Interstitial Lung Disease After Autologous Hematopoietic Stem Cell Transplantation
Jacopo Ciaffi¹, Nina van Leeuwen ², Maaike Boonstra ², Lucia Kroft ³, Anne Schouffoer ³, Maarten Ninaber ², Thomas Huizinga ² and Jeska de Vries-Bouwstra ², ¹Leiden University Medical Center, Bologna, Emilia-Romagna, Italy, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Three trials demonstrated the overall superiority of autologous hematopoietic stem cell transplantation (HSCT) compared to pulsed cyclophosphamide (CYC) in SSc. An improvement in forced…
Abstract Number: 2607 • 2019 ACR/ARP Annual Meeting
Ultrasound Detection of Calcinosis and Correlation with Ulnar Artery Occlusion in Patients with Systemic Sclerosis
Robert Fairchild¹, Melody Chung ¹, Laurel Sharpless ¹, Shufeng Li ² and Lorinda Chung ¹, ¹Stanford University, Palo Alto, CA, ²Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA
Background/Purpose: Systemic Sclerosis (SSc) is a progressive fibrotic and vascular disease affecting multiple organs. Calcinosis cutis in SSc is characterized by calcium deposition in the…
Abstract Number: 2608 • 2019 ACR/ARP Annual Meeting
Subsets in Systemic Sclerosis-ILD: Working Towards Consensus-Based Definitions
David Roofeh¹, Kevin Brown ², Donald Tashkin ³, Shervin Assassi ⁴, Shaney Barratt ⁵, Elana Bernstein ⁶, Nitin Bhatt ⁷, Lorinda Chung ⁸, Harold Collard ⁹, Richard Conway ¹⁰, Paul Dellaripa ¹¹, Christopher Denton ¹², Oliver Distler ¹³, Robyn Domsic ¹⁴, Tracy J. Doyle ¹⁵, Puneet Garcha ¹⁶, Nishant Gupta ¹⁷, Anna Maria Hoffmann-Vold ¹⁸, Vivien Hsu ¹⁹, Francesca Ingegnoli ²⁰, Kerri Johannson ²¹, Bashar Kahaleh ²², Leticia Kawano-Dourado ²³, Ella Kazerooni ¹, Surabhi Khanna ¹⁷, Peter Korsten ²⁴, Celia JF Lin ²⁵, Toby Maher ²⁶, Stephen Mathai ²⁷, Fernando Martinez ²⁸, Eric Matteson ²⁹, Vivek Nagaraja ³⁰, Chester Oddis ³¹, Juan Ovalles-Bonilla ³², John Pauling ³³, Ganesh Raghu ³⁴, Ignasi Rodriguez-Pinto ³⁵, Ivan Rosas ¹⁵, James Seibold ³⁶, Virginia Steen ³⁷, Vibeke Strand ³⁸, Elizabeth Volkmann ³⁹, Dharshan Vummidi ³⁰, Simon Walsh ⁴⁰, Donald Zoz ⁴¹, Athol Wells ⁴² and Dinesh Khanna ⁴³, ¹University of Michigan, Ann Arbor, ²National Jewish Health, Denver, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁵North Bristol NHS Trust, Bristol, England, United Kingdom, ⁶Columbia University, New York City, ⁷Ohio State University Wexner Medical Center, Columbus, ⁸Stanford University, Palo Alto, CA, ⁹University of California San Fransisco, San Fransisco, ¹⁰Blackrock Clinic, Dublin, Ireland, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ¹³Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ¹⁴University of Pittsburgh, Pittsburgh, PA, ¹⁵Brigham and Women's Hospital, Harvard Medical School, Boston, ¹⁶Baylor Scott & White Health, Dallas, ¹⁷University of Cincinnati, Cincinnati, ¹⁸Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ¹⁹Rutgers- RWJ Medical School, SOUTH PLAINFIELD, NJ, ²⁰Division of Clinical Rheumatology, ASST Pini-CTO, Università degli Studi di Milano, Department of Clinical Sciences and Community Health, Milan, Italy, Milano, Italy, ²¹University of Calgary, Calgary, ²²University of Toledo, Toledo, OH, ²³University of Sao Paulo, Sao Paulo, Brazil, ²⁴University Medical Center Göttingen, Göttingen, Germany, ²⁵Genentech, San Fransisco, ²⁶National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom, ²⁷John Hopkins Pulmonary and Critical Care Medicine, Baltimore, ²⁸Will Cornell Medicine Pulmonary & Critical Care Medicine, New York, ²⁹Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ³⁰University of Michigan, Ann Arbor, MI, ³¹University of Pittsburgh Medical Center, Pittsburgh, PA, ³²Hospital Gregorio Marañón, Madrid, Spain, ³³Department of Rheumatology, Royal National Hospital of Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, England, United Kingdom, ³⁴University of Washington, Seattle, USA, Seattle, ³⁵University of Barcelona, Barcelona, Spain, ³⁶Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, ³⁷Georgetown University, Washington, D.C., USA, Georgetown, ³⁸Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ³⁹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴⁰Kings College London, London, United Kingdom, ⁴¹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ⁴²Royal Bromptom Hospital, London, United Kingdom, ⁴³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Systemic sclerosis associated interstitial lung disease (SSc-ILD) is heterogeneous, with varying degrees of severity and risk of disease progression. No consensus-based definitions of disease…
Abstract Number: 2609 • 2019 ACR/ARP Annual Meeting
Anti-angiogenic VEGF-A165b Is Associated with Systemic Sclerosis Peripheral Vasculopathy
Victoria Flower¹, Shaney Barratt ², Darren Hart ³, Amanda Mackenzie ⁴, Jacqueline Shipley ³, Stephen Ward ⁴ and John Pauling ¹, ¹Department of Rheumatology, Royal National Hospital of Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, England, United Kingdom, ²North Bristol NHS Trust, Bristol, England, United Kingdom, ³Department of Clinical Measurement, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, England, United Kingdom, ⁴Centre for Therapeutic Innovation & Department of Pharmacy and Pharmacology, University of Bath, Bath, England, United Kingdom
Background/Purpose: The anti-angiogenic isoform of Vascular Endothelial Growth Factor-A (VEGF-A165b) has been implicated in Systemic sclerosis (SSc) vasculopathy. High frequency ultrasound (HFUS) is a novel…
Abstract Number: 2610 • 2019 ACR/ARP Annual Meeting
Relationship Between Parenchymal and Vascular Features in Systemic Sclerosis-Interstitial Lung Disease: Results from Quantitative Analysis of Chest Computed Tomography
Cosimo Bruni¹, Mariaelena Occhipinti ², Gianna Camiciottoli ³, Maurizio Bartolucci ⁴, Michael Pienn ⁵, Gemma Lepri ¹, Alessio Fabbrizzi ³, Alessandra Tottoli ¹, Giulia Ciardi ³, Dilia Giuggioli ⁶, Giovanna Cuomo ⁷, Francesco Masini ⁷, Andrea Olschewski ⁵, Federico Lavorini ³, Stefano Colagrande ⁸ and Marco Matucci-Cerinic ⁹, ¹Dept. Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ²Dept. Experimental and Clinical Medicine, Div. Pneumology and Div. Radiology II, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ³Dept. Experimental and Clinical Medicine, Div. Pneumology, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ⁴Dept. of Services, Div. Emergency-Urgency Radiology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, ⁵Ludwig Boltzmann Institute for Lung Vascular Research, Institute of Physiology, Medical University of Graz, Graz, Austria, ⁶Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy, ⁷Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Naples, Italy, ⁸Dept. Experimental and Clinical Medicine, Div. Radiology II, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ⁹University of Florence, Department of Medicine, Florence, Italy, Florence, Italy
Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension negatively impact on Systemic sclerosis (SSc) prognosis. Chest computed tomography (CT) is the gold standard in…
Abstract Number: 2611 • 2019 ACR/ARP Annual Meeting
Mesenchymal Stem Cells in Scleroderma: A Systematic Review
Rossana Mejia-Romero ¹, Natalia Aguilera², Juan Pablo Alzate-Granados ³, C Escobar -Soto ⁴, Claudia Mendoza-Pinto ⁵, Mario García-Carrasco ⁵ and Adriana Rojas-Villarraga ⁶, ¹Center for Arthritis and Rehabilitation (CAYRE IPS) ,University of Barcolena, Bogotá, Distrito Capital de Bogota, Colombia, ²Fundacion Universitaria de Ciencias de La Salud-FUCS, Bogotá, Distrito Capital de Bogota, Colombia, ³Fundacion Universitaria de Ciencias de La Salud-FUCS, Bogota, Distrito Capital de Bogota, Colombia, ⁴TRUSTEM, Bogotá, Distrito Capital de Bogota, Colombia, ⁵Systemic Autoimmune Diseases Research Unit, Hospital de Especialidades, UMAE CMNMAC - CIBIOR, Instituto Mexicano del Seguro Social. Department of Rheumatology and Immunology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico, ⁶Fundacion Universitaria de Ciencias de La Salud-FUCS. Hospital Infantil Universitario San José., Bogotá, Distrito Capital de Bogota, Colombia
Background/Purpose: Scleroderma (systemic scleroderma or systemic sclerosis, SSc), is a highly heterogeneous autoimmune disease of unknown etiology, with a high rate of therapeutic failure and…
Abstract Number: 2612 • 2019 ACR/ARP Annual Meeting
Minocycline for Refractory Calcinosis in Systemic Sclerosis: A Single-Centre Observational Cohort Study
Carmen Fonseca¹, Voon Ong ² and Christopher Denton ³, ¹UCL Medical School, Royal Free Campus, London, United Kingdom, ²UCL Medical School, Royal Free Campus, London, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: Calcinosis represents a major challenge for patients with systemic sclerosis (SSc) for which there is no standard therapy. Minocycline has been proposed for treatment…
Abstract Number: 2613 • 2019 ACR/ARP Annual Meeting
Hsp90 as a Potential Biomarker of Lung and Skin Involvement in Patients with Systemic Sclerosis
Hana Storkanova¹, Sabina Oreska ², Maja Spiritovic ³, Barbora Hermankova ⁴, Kristyna Bubova ¹, Martin Komarc ⁵, Karel Pavelka ², Jiri Vencovsky ¹, Jörg Distler ⁶, Ladislav Senolt ², Radim Becvar ² and Michal Tomcik ², ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ³Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic, Prague 2, Hlavni mesto Praha, Czech Republic, ⁴Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Department of Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Our previous study demonstrated that Hsp90 is overexpressed in the skin of patients with systemic sclerosis (SSc), in cultured SSc fibroblasts and preclinical models…
Abstract Number: 2614 • 2019 ACR/ARP Annual Meeting
Association of Body Composition in Scleroderma Patients with Disease Activity, Serum Levels of Inflammatory Cytokines and Parameters of Nutrition and Lipid Metabolism
Sabina Oreska¹, Maja Spiritovic ², Petr Cesak ³, Michal Cesak ³, Hana Storkanova ⁴, Hana Smucrova ⁵, Barbora Hermankova ³, Olga Ruzickova ⁴, Herman Mann ¹, Karel Pavelka ¹, Ladislav Senolt ¹, Jiří Vencovský ¹, Radim Becvar ¹ and Michal Tomcik ¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ²Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic, Prague 2, Hlavni mesto Praha, Czech Republic, ³Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Fibrosis of the skin and visceral organs, especially digestive tract, and musculoskeletal involvement in systemic sclerosis (SSc) can have a negative impact on body…
Abstract Number: 2615 • 2019 ACR/ARP Annual Meeting
Cumulative Incidence, Survival and Predictors of Pulmonary Arterial Hypertension in Disease Subsets of Systemic Sclerosis: PAH Is Not Increased in Limited vs Diffuse Patients by Adjusted Competing Risk Analysis
Tatiana Nevskaya ¹, Yuxuan Jiang ¹, Mianbo Wang ² and Janet Pope³, ¹University of Western Ontario, London, ON, Canada, ²Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, ³Western University, London, ON, Canada
Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc), thought to be more commonly found among the limited cutaneous (lcSSc) compared…
Abstract Number: 2616 • 2019 ACR/ARP Annual Meeting
Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease—Analysis from the University of Michigan Scleroderma Cohort
Mirette Habib¹, Sara Jaafar ¹, Annie Park ¹, Suiyuan Huang ¹, Wen Ye ¹, Vivek Nagaraja ¹, Eric White ¹, Kevin Flaherty ² and Dinesh Khanna ³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial Lung Disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc) patients. Forced Vital Capacity (FVC, recorded as %…
Abstract Number: 2617 • 2019 ACR/ARP Annual Meeting
Responsiveness to Change of the Modified Rodnan Skin Score in a Phase I/II Double-Blind Randomized Placebo-Controlled Trial
Erica Bush ¹, Vivek Nagaraja ¹, Robert Lafyatis ² and Dinesh Khanna³, ¹University of Michigan, Ann Arbor, MI, ²University of Pittsburgh Department of Medicine, Pittsburgh, ³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Modified Rodnan skin score (mRSS) is used as primary and secondary outcome measure in different trials of diffuse cutaneous systemic sclerosis (dcSSc) 1. As…
Abstract Number: 2618 • 2019 ACR/ARP Annual Meeting
Anti-RNPC-3 Antibodies Are Associated with Nuclear Speckled Immunofluorescence Pattern and Enriched in Triple Negative Systemic Sclerosis Patients
Michael Mahler¹, Fabrece Roup ¹, Chelsea Bentow ¹, Marie Hudson ², Murray Baron ³, May Choi ⁴ and Marvin Fritzler ⁵, ¹Inova Diagnostics, San Diego, CA, ²Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ³Jewish General Hospital, McGill University, Montreal, Canada, ⁴Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Anti-nuclear antibodies (ANA) are present in approximately 90% of sera from systemic sclerosis (SSc) patients and play an important diagnostic and prognostic role in…
Abstract Number: 2619 • 2019 ACR/ARP Annual Meeting
Rituximab for Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of Observational Studies
Giovanni Pomponio¹, Vincenzo Menditto ², Giulia Rossetti ³, Alessia Angeletti ³, Diletta Olivari ³ and Armando Gabrielli ³, ¹Clinica Medica Ospedali Riuniti di Ancona, Ancona, Italy, ²Internal Medicina Ospedali Riuniti di Ancona, ancona, Italy, ³Clinica Medica Università Politecnica delle Marche, Ancona, Italy
Background/Purpose: More than 40 studies containing data about adults affected by EGPA treated with Rituximab (RTX) have been published in the last decade. Nevertheless, due…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].